![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CX3CL1 |
Gene summary for CX3CL1 |
![]() |
Gene information | Species | Human | Gene symbol | CX3CL1 | Gene ID | 6376 |
Gene name | C-X3-C motif chemokine ligand 1 | |
Gene Alias | ABCD-3 | |
Cytomap | 16q21 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0N0N7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6376 | CX3CL1 | LZE4T | Human | Esophagus | ESCC | 2.32e-10 | 1.04e-01 | 0.0811 |
6376 | CX3CL1 | LZE5T | Human | Esophagus | ESCC | 2.94e-03 | -2.92e-04 | 0.0514 |
6376 | CX3CL1 | LZE8T | Human | Esophagus | ESCC | 6.67e-08 | 2.02e-01 | 0.067 |
6376 | CX3CL1 | LZE21T | Human | Esophagus | ESCC | 1.83e-05 | 5.53e-01 | 0.0655 |
6376 | CX3CL1 | P1T-E | Human | Esophagus | ESCC | 9.34e-05 | 6.28e-01 | 0.0875 |
6376 | CX3CL1 | P2T-E | Human | Esophagus | ESCC | 4.34e-04 | 4.40e-01 | 0.1177 |
6376 | CX3CL1 | P4T-E | Human | Esophagus | ESCC | 1.33e-11 | -3.29e-02 | 0.1323 |
6376 | CX3CL1 | P5T-E | Human | Esophagus | ESCC | 3.37e-06 | 2.72e-01 | 0.1327 |
6376 | CX3CL1 | P8T-E | Human | Esophagus | ESCC | 1.20e-36 | 1.27e+00 | 0.0889 |
6376 | CX3CL1 | P10T-E | Human | Esophagus | ESCC | 3.73e-05 | -1.81e-01 | 0.116 |
6376 | CX3CL1 | P11T-E | Human | Esophagus | ESCC | 2.52e-07 | 7.25e-01 | 0.1426 |
6376 | CX3CL1 | P12T-E | Human | Esophagus | ESCC | 3.44e-04 | 1.46e-01 | 0.1122 |
6376 | CX3CL1 | P15T-E | Human | Esophagus | ESCC | 6.94e-14 | 5.78e-01 | 0.1149 |
6376 | CX3CL1 | P16T-E | Human | Esophagus | ESCC | 3.50e-03 | 2.44e-01 | 0.1153 |
6376 | CX3CL1 | P22T-E | Human | Esophagus | ESCC | 1.36e-16 | 4.19e-02 | 0.1236 |
6376 | CX3CL1 | P23T-E | Human | Esophagus | ESCC | 2.74e-03 | 6.08e-02 | 0.108 |
6376 | CX3CL1 | P26T-E | Human | Esophagus | ESCC | 1.01e-22 | 7.38e-01 | 0.1276 |
6376 | CX3CL1 | P27T-E | Human | Esophagus | ESCC | 1.87e-05 | 2.31e-01 | 0.1055 |
6376 | CX3CL1 | P30T-E | Human | Esophagus | ESCC | 3.09e-08 | 7.85e-01 | 0.137 |
6376 | CX3CL1 | P32T-E | Human | Esophagus | ESCC | 1.11e-08 | 1.12e-01 | 0.1666 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:2001233111 | Esophagus | ESCC | regulation of apoptotic signaling pathway | 256/8552 | 356/18723 | 4.11e-24 | 1.04e-21 | 256 |
GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
GO:0097191111 | Esophagus | ESCC | extrinsic apoptotic signaling pathway | 159/8552 | 219/18723 | 4.12e-16 | 2.94e-14 | 159 |
GO:2001234111 | Esophagus | ESCC | negative regulation of apoptotic signaling pathway | 161/8552 | 224/18723 | 1.24e-15 | 8.09e-14 | 161 |
GO:004312318 | Esophagus | ESCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 132/8552 | 186/18723 | 2.07e-12 | 8.58e-11 | 132 |
GO:2001236111 | Esophagus | ESCC | regulation of extrinsic apoptotic signaling pathway | 111/8552 | 151/18723 | 2.97e-12 | 1.18e-10 | 111 |
GO:0043122110 | Esophagus | ESCC | regulation of I-kappaB kinase/NF-kappaB signaling | 167/8552 | 249/18723 | 6.11e-12 | 2.32e-10 | 167 |
GO:000724919 | Esophagus | ESCC | I-kappaB kinase/NF-kappaB signaling | 183/8552 | 281/18723 | 3.02e-11 | 1.01e-09 | 183 |
GO:1902905111 | Esophagus | ESCC | positive regulation of supramolecular fiber organization | 142/8552 | 209/18723 | 5.51e-11 | 1.76e-09 | 142 |
GO:1902903111 | Esophagus | ESCC | regulation of supramolecular fiber organization | 237/8552 | 383/18723 | 9.06e-11 | 2.75e-09 | 237 |
GO:005149520 | Esophagus | ESCC | positive regulation of cytoskeleton organization | 147/8552 | 226/18723 | 2.93e-09 | 6.38e-08 | 147 |
GO:003158919 | Esophagus | ESCC | cell-substrate adhesion | 221/8552 | 363/18723 | 3.06e-09 | 6.62e-08 | 221 |
GO:001081020 | Esophagus | ESCC | regulation of cell-substrate adhesion | 144/8552 | 221/18723 | 3.55e-09 | 7.45e-08 | 144 |
GO:0051235110 | Esophagus | ESCC | maintenance of location | 200/8552 | 327/18723 | 1.01e-08 | 2.02e-07 | 200 |
GO:000701527 | Esophagus | ESCC | actin filament organization | 259/8552 | 442/18723 | 2.37e-08 | 4.50e-07 | 259 |
GO:0070997111 | Esophagus | ESCC | neuron death | 216/8552 | 361/18723 | 3.49e-08 | 6.45e-07 | 216 |
GO:004578527 | Esophagus | ESCC | positive regulation of cell adhesion | 255/8552 | 437/18723 | 5.07e-08 | 9.11e-07 | 255 |
GO:000756820 | Esophagus | ESCC | aging | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
GO:0032970111 | Esophagus | ESCC | regulation of actin filament-based process | 231/8552 | 397/18723 | 2.91e-07 | 4.20e-06 | 231 |
GO:001081126 | Esophagus | ESCC | positive regulation of cell-substrate adhesion | 84/8552 | 123/18723 | 3.18e-07 | 4.50e-06 | 84 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa05163210 | Esophagus | ESCC | Human cytomegalovirus infection | 148/4205 | 225/8465 | 5.73e-07 | 4.00e-06 | 2.05e-06 | 148 |
hsa0466817 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa0516338 | Esophagus | ESCC | Human cytomegalovirus infection | 148/4205 | 225/8465 | 5.73e-07 | 4.00e-06 | 2.05e-06 | 148 |
hsa0516312 | Liver | Cirrhotic | Human cytomegalovirus infection | 87/2530 | 225/8465 | 2.67e-03 | 1.10e-02 | 6.76e-03 | 87 |
hsa0516313 | Liver | Cirrhotic | Human cytomegalovirus infection | 87/2530 | 225/8465 | 2.67e-03 | 1.10e-02 | 6.76e-03 | 87 |
hsa046684 | Liver | HCC | TNF signaling pathway | 73/4020 | 114/8465 | 2.53e-04 | 1.19e-03 | 6.63e-04 | 73 |
hsa0516322 | Liver | HCC | Human cytomegalovirus infection | 131/4020 | 225/8465 | 6.86e-04 | 2.77e-03 | 1.54e-03 | 131 |
hsa0466811 | Liver | HCC | TNF signaling pathway | 73/4020 | 114/8465 | 2.53e-04 | 1.19e-03 | 6.63e-04 | 73 |
hsa0516332 | Liver | HCC | Human cytomegalovirus infection | 131/4020 | 225/8465 | 6.86e-04 | 2.77e-03 | 1.54e-03 | 131 |
hsa0516326 | Prostate | BPH | Human cytomegalovirus infection | 74/1718 | 225/8465 | 4.87e-06 | 3.92e-05 | 2.43e-05 | 74 |
hsa046688 | Prostate | BPH | TNF signaling pathway | 41/1718 | 114/8465 | 6.86e-05 | 4.35e-04 | 2.69e-04 | 41 |
hsa05163111 | Prostate | BPH | Human cytomegalovirus infection | 74/1718 | 225/8465 | 4.87e-06 | 3.92e-05 | 2.43e-05 | 74 |
hsa0466815 | Prostate | BPH | TNF signaling pathway | 41/1718 | 114/8465 | 6.86e-05 | 4.35e-04 | 2.69e-04 | 41 |
hsa0516327 | Prostate | Tumor | Human cytomegalovirus infection | 74/1791 | 225/8465 | 2.27e-05 | 1.79e-04 | 1.11e-04 | 74 |
hsa0466821 | Prostate | Tumor | TNF signaling pathway | 40/1791 | 114/8465 | 3.88e-04 | 2.07e-03 | 1.29e-03 | 40 |
hsa0516336 | Prostate | Tumor | Human cytomegalovirus infection | 74/1791 | 225/8465 | 2.27e-05 | 1.79e-04 | 1.11e-04 | 74 |
hsa0466831 | Prostate | Tumor | TNF signaling pathway | 40/1791 | 114/8465 | 3.88e-04 | 2.07e-03 | 1.29e-03 | 40 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
CX3CL1 | CX3CR1 | CX3CL1_CX3CR1 | CX3C | Breast | ADJ |
CX3CL1 | CX3CR1 | CX3CL1_CX3CR1 | CX3C | Breast | Healthy |
CX3CL1 | CX3CR1 | CX3CL1_CX3CR1 | CX3C | Lung | ADJ |
CX3CL1 | CX3CR1 | CX3CL1_CX3CR1 | CX3C | Lung | MIAC |
CX3CL1 | CX3CR1 | CX3CL1_CX3CR1 | CX3C | Prostate | ADJ |
CX3CL1 | CX3CR1 | CX3CL1_CX3CR1 | CX3C | Prostate | BPH |
CX3CL1 | CX3CR1 | CX3CL1_CX3CR1 | CX3C | THCA | ADJ |
CX3CL1 | CX3CR1 | CX3CL1_CX3CR1 | CX3C | THCA | Cancer |
CX3CL1 | CX3CR1 | CX3CL1_CX3CR1 | CX3C | THCA | PTC |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CX3CL1 | SNV | Missense_Mutation | rs773596059 | c.1189N>A | p.Val397Met | p.V397M | P78423 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-DM-A1D6-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CX3CL1 | SNV | Missense_Mutation | c.667N>A | p.Asp223Asn | p.D223N | P78423 | protein_coding | tolerated(0.13) | benign(0.015) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD | |
CX3CL1 | SNV | Missense_Mutation | rs199662906 | c.1154N>A | p.Arg385Gln | p.R385Q | P78423 | protein_coding | deleterious(0.02) | possibly_damaging(0.707) | TCGA-G4-6315-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | SD |
CX3CL1 | SNV | Missense_Mutation | rs529786529 | c.692N>T | p.Ala231Val | p.A231V | P78423 | protein_coding | tolerated(0.25) | benign(0) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CX3CL1 | SNV | Missense_Mutation | novel | c.428C>A | p.Ser143Tyr | p.S143Y | P78423 | protein_coding | deleterious(0.02) | possibly_damaging(0.459) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CX3CL1 | SNV | Missense_Mutation | novel | c.283N>A | p.Ala95Thr | p.A95T | P78423 | protein_coding | tolerated(0.31) | benign(0.003) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
CX3CL1 | SNV | Missense_Mutation | c.771G>T | p.Glu257Asp | p.E257D | P78423 | protein_coding | deleterious(0.03) | benign(0.111) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CX3CL1 | SNV | Missense_Mutation | c.771G>T | p.Glu257Asp | p.E257D | P78423 | protein_coding | deleterious(0.03) | benign(0.111) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CX3CL1 | SNV | Missense_Mutation | novel | c.114G>T | p.Lys38Asn | p.K38N | P78423 | protein_coding | tolerated(0.21) | benign(0.012) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
CX3CL1 | SNV | Missense_Mutation | novel | c.563N>C | p.Val188Ala | p.V188A | P78423 | protein_coding | tolerated(0.91) | benign(0) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6376 | CX3CL1 | CELL SURFACE, DRUGGABLE GENOME | COMPLETE FREUND&APOS;S ADJUVANT | 15993821 | ||
6376 | CX3CL1 | CELL SURFACE, DRUGGABLE GENOME | ATEZOLIZUMAB | ATEZOLIZUMAB | 25428504 |
Page: 1 |